Crystal Pharmatech’s November 4 announcement confirms ED-1 service in Suzhou. Its service page describes integration with solid-form screening for small crystals and pharmaceutical solid forms.
Date note: the November 3 Chinese notice and November 4, 7:15 a.m. ET English release concern the same installation. This updates the existing record. Earlier notice: https://mp.weixin.qq.com/s/Zq_2xoI_HbH2RcKP_uqisg
The service page lists sample amounts from 1 mg and expedited reporting from 48 hours, subject to feasibility review. Additional work, including absolute configuration, may take longer. Specifications: https://www.crystalpharmatech.com/microed-services.html
Equipment provider: ELDICO Scientific.
Why it may matter
Connecting screened forms with structural evidence may support form selection; feasibility remains sample dependent.
The interpretation above is analysis, not a conclusion attributed to the original source.
This article explores how Microcrystal Electron Diffraction (MicroED) is set to revolutionize drug polymorph research workflows. Drawing upon recent news, official websites, and LinkedIn updates from Crystal Pharmatech and Eldico, it clearly distinguishes between verified facts, industry viewpoints, and information pending verification.
Direct Electron lists a REyes webinar for November 10, 2026, at noon Eastern Time. It will discuss diffraction-guided screening, automated acquisition and structure solution, including integration with SerialEM.
The NYSBC, SEMC, and NCCAT course is scheduled for November 2–4, 2026, in New York. Its November 4 agenda includes automation and machine learning, microscope setup, acquisition, and direct-detector practicals, with optional practice on November 5.
Continue your research
All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.
